An ACE inhibitor (IC₅₀ = 6.3 nM) that does not exhibit a domain preference for binding either the C- or N-terminal active sites of the somatic form of ACE; reversibly inhibits LTA4 hydrolase, inhibiting LTB4 synthesis (IC₅₀ = 14 μM).